(S)-Bupropion Enantiomer Segmentation for Reduced Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bupropion treatments often require higher doses of racemic bupropion, which may not be as effective or efficient in achieving the desired pharmacokinetic and therapeutic effects.
Innovation Solution
Development of dosage forms containing an enantiomeric excess of (S)-bupropion, which is at least 95% enantiomerically pure, allowing for reduced dosing while achieving similar pharmacokinetic and therapeutic effects as racemic bupropion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If racemic bupropion is used at higher doses to achieve therapeutic effects, then the therapeutic coverage is improved, but the potential adverse effects and loss of substance increase
Solution Approach 1:
The racemic mixture of bupropion is segmented into its individual enantiomers ((R)-bupropion and (S)-bupropion). The patent isolates and utilizes the therapeutically active (S)-enantiomer separately from the (R)-enantiomer, allowing for targeted dosing that achieves therapeutic effects while minimizing adverse effects associated with the inactive or less active enantiomer.
Solution Approach 2:
The patent extracts the therapeutically active (S)-bupropion enantiomer from the racemic mixture. By taking out only the effective component, the formulation achieves the desired therapeutic effect at lower doses, thereby reducing the harmful effects and substance loss associated with administering the full racemic mixture at higher doses.
2Reliability
If racemic bupropion is administered at higher doses to ensure therapeutic coverage, then the reliability of treatment is improved, but the quantity of substance required increases
Solution Approach 1:
The racemic mixture is segmented into individual enantiomers, allowing the patent to isolate the therapeutically active (S)-bupropion. This segmentation enables precise dosing of only the effective component, reducing the total quantity of substance required while maintaining reliable therapeutic coverage.
Solution Approach 2:
The active (S)-bupropion enantiomer is extracted from the racemic mixture. This extraction allows for optimized dosing where only the necessary amount of therapeutically active substance is administered, minimizing waste and reducing the overall quantity of substance required for effective treatment.
3Loss of substance
If enantiomerically pure (S)-bupropion is used at reduced doses, then the loss of substance is reduced, but the manufacturing precision requirements increase
Solution Approach 1:
The racemic mixture is segmented into individual enantiomers through resolution techniques. This segmentation process, while requiring manufacturing precision, enables the isolation of the therapeutically active (S)-bupropion, which then allows for reduced dosing and minimized substance loss in clinical use.
Solution Approach 2:
The active (S)-bupropion enantiomer is extracted and isolated from the racemic mixture using chiral resolution or other enantioselective methods. Although this extraction process demands high manufacturing precision to achieve the required enantiomeric purity (e.g., >95% or >98% ee), it ultimately enables reduced dosing and minimizes substance loss during administration.
Data Source
AI summary
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.